July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Update on the clinical trial using cultivated corneal endothelial cell injection
Author Affiliations & Notes
  • Shigeru Kinoshita
    Frontier Medical Science for Ophth, Kyoto Prefectural Univ of Med, Kamigyo-Ku, Japan
  • Footnotes
    Commercial Relationships   Shigeru Kinoshita, Senju Pharmaceutical Co. (P)
  • Footnotes
    Support   grants from the Highway Program for Realization of Regenerative Medicine from the Japan Agency for Medical Research and Development, and the Research Project for Practical Applications of Regenerative Medicine from the Japanese Ministry of Health, Labour and Welfare.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2003. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shigeru Kinoshita; Update on the clinical trial using cultivated corneal endothelial cell injection. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2003. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : Understanding the biological and immunological characteristics of human corneal endothelial cells (hCECs) is an essential key to the establishment of new strategies for treating corneal endothelial dysfunction. In this direction, our research group has been developing a ‘cultured hCEC-injection therapy’ involving the injection of cultured human CECs into the anterior chamber of bullous keratopathy, which may be a completely new strategy of the treatment. For this purpose, non-proliferative corneal endothelial cells from donated corneas have been induced to proliferate, without inducing cell state transition (CST). Our findings have shown this approach to be promising. In order to apply this novel approach to actual clinical practice, several key safety issues must be addressed and assured from the aspect of regulatory science.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.